Protalix BioTherapeutics (PLX) Competitors $1.54 -0.05 (-3.14%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.56 +0.02 (+1.62%) As of 09/5/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. EOLS, ALMS, CMPX, TECX, KOD, ETON, ARCT, RGNX, ITOS, and ESPRShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Evolus (EOLS), Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Evolus Alumis Compass Therapeutics Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Do insiders & institutionals have more ownership in PLX or EOLS? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 5.9% of Evolus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer PLX or EOLS? In the previous week, Evolus had 10 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 11 mentions for Evolus and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.73 beat Evolus' score of 1.59 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evolus 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger earnings and valuation, PLX or EOLS? Protalix BioTherapeutics has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$61.95M1.98$8.31M$0.0722.00Evolus$277.94M1.78-$50.42M-$0.98-7.82 Do analysts prefer PLX or EOLS? Protalix BioTherapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 874.03%. Evolus has a consensus price target of $21.25, suggesting a potential upside of 177.42%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is PLX or EOLS more profitable? Protalix BioTherapeutics has a net margin of -21.03% compared to Evolus' net margin of -22.31%. Protalix BioTherapeutics' return on equity of -30.89% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Evolus -22.31%-759.04%-24.63% Which has more volatility & risk, PLX or EOLS? Protalix BioTherapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. SummaryProtalix BioTherapeutics beats Evolus on 10 of the 16 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$122.79M$290.97M$5.79B$21.35BDividend YieldN/AN/A6.71%3.50%P/E Ratio-11.85N/A76.0829.63Price / Sales1.98474.43460.9349.11Price / Cash17.8022.4436.9624.54Price / Book3.2810.9411.484.55Net Income$8.31M-$111.61M$3.29B$999.70M7 Day Performance-0.65%2.42%1.27%0.58%1 Month Performance4.05%2.41%7.94%5.66%1 Year Performance54.00%-14.20%62.93%17.40% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics3.136 of 5 stars$1.54-3.1%$15.00+874.0%+49.5%$122.79M$61.95M-11.85200Positive NewsEOLSEvolus4.6076 of 5 stars$7.63+1.5%$21.25+178.5%-48.9%$493.55M$266.27M-7.79170News CoveragePositive NewsShort Interest ↓ALMSAlumis3.0785 of 5 stars$4.64-1.3%$20.17+334.6%-61.7%$482.86MN/A0.00N/ACMPXCompass Therapeutics2.7518 of 5 stars$3.49flat$12.89+269.3%+130.9%$482.61M$850K-7.7620Positive NewsTECXTectonic Therapeutic3.1291 of 5 stars$25.54-0.1%$80.33+214.5%-8.0%$477.91MN/A-6.32120News CoveragePositive NewsAnalyst ForecastKODKodiak Sciences3.1153 of 5 stars$9.04+0.8%$11.75+30.0%+324.2%$477.51MN/A-2.3890Trending NewsAnalyst RevisionETONEton Pharmaceuticals2.0111 of 5 stars$17.31+0.2%$29.67+71.4%+283.3%$464.21M$39.01M-108.1920Positive NewsARCTArcturus Therapeutics3.3878 of 5 stars$17.01-1.7%$50.57+197.3%-5.2%$461.90M$152.31M-7.63180Trending NewsAnalyst ForecastAnalyst RevisionRGNXREGENXBIO4.5997 of 5 stars$8.93-0.9%$28.38+217.7%-14.7%$451.09M$83.33M-2.60370News CoveragePositive NewsGap UpITOSiTeos Therapeutics3.6906 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790News CoverageShort Interest ↓ESPREsperion Therapeutics3.8575 of 5 stars$2.22+0.5%$7.00+215.3%+55.8%$447.60M$332.31M-4.53200Positive NewsOptions Volume Related Companies and Tools Related Companies Evolus Alternatives Alumis Alternatives Compass Therapeutics Alternatives Tectonic Therapeutic Alternatives Kodiak Sciences Alternatives Eton Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives REGENXBIO Alternatives iTeos Therapeutics Alternatives Esperion Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
